Health Catalyst Earnings Call: Profit Gains, Growth Risks

Health Catalyst ((HCAT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Health Catalyst’s latest earnings call struck a cautious but constructive tone. Management highlighted strong margin expansion, robust adjusted EBITDA growth, and solid technology revenue gains as evidence that restructuring efforts are working. Yet investors were warned that sizeable impairments, revenue headwinds, and migration-related churn risks leave the near-term outlook highly uncertain.

Full-Year Revenue and Technology Growth

Health Catalyst reported 2025 revenue of $311.1 million, inching up just 1% year over year and underscoring muted top-line momentum. The bright spot was technology revenue, which rose 7% to $208.3 million, showing that the core software and platform business is gaining traction even as overall growth remains modest.

Adjusted EBITDA and Margin Expansion

Profitability metrics were a clear highlight, with adjusted EBITDA jumping 59% to $41.4 million for 2025 and Q4 EBITDA rising to $13.8 million from $7.9 million a year ago. Adjusted gross margin improved sharply to 53.5% in Q4 and 51.1% for the year, reflecting tangible benefits from restructuring and tighter cost control.

Improved Operating Efficiency

Operating efficiency continued to trend favorably as adjusted operating expenses fell to $117.7 million, or 38% of revenue, down from 40% the prior year. In Q4, adjusted operating expenses dropped to $26.2 million, or 35% of revenue, including a $2 million sequential reduction driven by workforce optimization and other cost actions.

Client Acquisition and Retention Indicators

On the commercial front, Health Catalyst closed 32 net new logos in 2025, beating its revised target but missing original expectations of 40. Dollar-based retention across key technology offerings landed at 90%, while new customers brought in average recurring and non-recurring revenue near the midpoint of the $300,000 to $700,000 range.

Balance Sheet Liquidity

The company ended the year with about $96 million in cash, cash equivalents, and short-term investments, providing a reasonable liquidity cushion. This sits against $161 million of term loan debt, leaving leverage meaningful but manageable as long as the company sustains positive adjusted EBITDA and disciplined spending.

Strategic and Leadership Actions

A newly promoted CEO is reshaping the organization, sharpening commercial focus and simplifying the company’s narrative for customers and investors. Management has installed general managers for interoperability and cybersecurity, is searching for new operating and marketing leaders, and is prioritizing bookings, retention, AI-focused R&D, and clearer reporting to drive better execution.

Quarterly Revenue Decline

Despite full-year progress, Q4 revenue slipped 6% year over year to $74.7 million, signaling ongoing growth challenges. Management also guided Q1 2026 revenue down sequentially to a range of $68 million to $70 million, indicating that near-term headwinds are not yet behind the company.

Professional Services Revenue Pressure

Professional services remained a weak spot, falling 8% in 2025 to $103.8 million, with Q4 services revenue at $22.8 million. The company attributed this slide to deliberate reductions in full-time services offerings and the exit from unprofitable pilot arrangements, trading near-term revenue for improved quality and profitability of engagements.

Large GAAP Impairment and Worsened GAAP Loss

Headline GAAP results were hit hard by a $110.2 million impairment of goodwill and intangible assets recorded in 2025. That charge swelled the GAAP net loss to $178 million, more than double the prior year’s $69.5 million loss, and highlighted the gap between accounting results and improving adjusted profitability.

Migration-Related ARR at Risk (DOS to Ignite)

A major concern centers on the shift from the company’s DOS platform to its newer Ignite offering, which is putting a meaningful chunk of recurring revenue at risk. Management disclosed $12.5 million of already notified downsell or churn plus about $52 million of additional DOS-related ARR, including $35 million tied to data infrastructure, under negotiation through 2027.

Near-Term Financial Pressure from Migration and Investments

These migrations, along with business exits, are already hitting the P&L, with Q1 pressure expected from reductions in TEMS revenue, data platform migrations, and non-recurring projects. At the same time, Health Catalyst is ramping spending on migration resources and AI- and India-based R&D, moves that may pinch margins in the short run but are aimed at a leaner, more scalable model later.

Guidance and Uncertainty

Looking ahead, the company only offered Q1 2026 guidance for revenue of $68 million to $70 million and adjusted EBITDA of $7 million to $8 million, reflecting the temporary drag from migration and restructuring. Management plans to provide full-year guidance by the next earnings call, but acknowledged that the ultimate impact of DOS-related churn and the pace of recovery remain uncertain.

Health Catalyst’s earnings call painted a picture of a company executing well on cost and margin improvement while grappling with real revenue and migration risks. Investors will be watching closely to see whether leadership can convert today’s disciplined restructuring and AI-enabled investments into sustainable growth once the current transition and contract renegotiations play out.